華熙生物(688363.SH):華熙天津透明質酸鈉及相關項目擬延期
格隆匯12月8日丨華熙生物(688363.SH)公佈,公司於2021年12月8日召開第一屆董事會第二十八次會議及第一屆監事會第二十三次會議,分別審議通過了《關於調整部分募投項目實施進度的議案》,同意華熙天津透明質酸鈉及相關項目(“天津項目”)實施進度調整至2022年4月前全部達到預定可使用狀態。
近期,天津項目300噸透明質酸原料生產線相關設備陸續完成調試,進入試生產驗收階段。相關產線驗收時,應天津經濟技術開發區試生產相關審批部門要求,產線的部分設計建造須按照國家最新標準進行調整升級。經公司審慎評估,天津項目預計將於2022年4月前,完成調整升級工作並正式投入生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.